Haverford Trust Co. lowered its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 2.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 75,281 shares of the biopharmaceutical company’s stock after selling 1,813 shares during the period. Haverford Trust Co.’s holdings in Bristol-Myers Squibb were worth $4,094,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the stock. American National Bank boosted its stake in shares of Bristol-Myers Squibb by 36.0% in the first quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 508 shares in the last quarter. Welch Investments LLC boosted its stake in shares of Bristol-Myers Squibb by 3.9% in the first quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 79 shares during the period. Crestwood Advisors Group LLC purchased a new stake in shares of Bristol-Myers Squibb during the first quarter worth about $116,000. State of Alaska Department of Revenue boosted its stake in shares of Bristol-Myers Squibb by 2.8% in the first quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 60 shares during the period. Finally, Prentiss Smith & Co. Inc. raised its position in shares of Bristol-Myers Squibb by 61.8% in the first quarter. Prentiss Smith & Co. Inc. now owns 2,333 shares of the biopharmaceutical company’s stock worth $127,000 after buying an additional 891 shares in the last quarter. 69.79% of the stock is owned by institutional investors and hedge funds.
Shares of Bristol-Myers Squibb Company (BMY) opened at 56.73 on Friday. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $60.86. The stock has a 50 day moving average of $55.80 and a 200-day moving average of $54.64. The company has a market capitalization of $93.03 billion, a PE ratio of 20.72 and a beta of 1.17.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter last year, the company earned $0.69 earnings per share. Bristol-Myers Squibb’s quarterly revenue was up 5.6% compared to the same quarter last year. Analysts predict that Bristol-Myers Squibb Company will post $2.97 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 56.73%.
BMY has been the subject of a number of research reports. Vetr upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $62.23 target price for the company in a research report on Wednesday, July 12th. BMO Capital Markets restated a “market perform” rating and set a $45.00 target price on shares of Bristol-Myers Squibb in a research report on Sunday, April 23rd. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Wednesday. BidaskClub upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Leerink Swann dropped their target price on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating for the company in a research report on Friday, July 28th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $62.12.
In other news, Director Theodore R. Samuels II purchased 6,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the transaction, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.23% of the stock is currently owned by company insiders.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.